A Cross-Domain Enterprise LIMS Architecture for Organ Bioprinting: Bridging R&D, Process Development, QC, and GMP Manufacturing
1. Niranjana Raghunathan, GSK, Scientist, United States
Organ-scale
three-dimensional (3D) bioprinting is poised to transform transplantation
medicine and advanced therapeutics; however, translation from laboratory
innovation to regulated, multi-site manufacturing remains constrained by
fragmentation across research (R&D), process development (PD), quality
control (QC), and GMP production. This paper presents a cross-domain enterprise
systems architecture that positions Laboratory Information Management Systems
(LIMS) as the digital backbone spanning discovery through commercial
manufacturing, establishing a continuous, auditable digital thread for organ
bioprinting. We define quantitative manufacturing and translation metrics
Reproducibility Index (RI), Throughput Scalability Factor (TSF), Protocol
Deviation Rate (PDR), and Documentation Completeness Score (DCS) and a
validation-by-design lifecycle aligned to GAMP5. The framework is grounded in
thirteen years of enterprise-scale LIMS and data-integrity leadership across
pharmaceutical R&D, QC, and manufacturing. This paper follows the SCIRP
structure and proposes a systems engineering framework integrating LIMS into
bioprinting. We argue that organ bioprinting will not become an industrial
discipline without cross-domain informatics governance, and we provide an
immediately actionable blueprint for implementation.
Organ Bioprinting Enterprise LIMS Digital Thread R&D Process Development QC GMP Systems Architecture GxP
This
work argues that the principal barrier to the industrialization of organ
bioprinting is not the pace of biological or materials innovation, but the
absence of manufacturing-grade digital governance, data continuity, and
lifecycle control. Through the synthesis of lessons from regulated
pharmaceutical manufacturing and the formulation of a cross-domain
architectural framework, we show how a LIMS-centered digital backbone can
provide the missing translational infrastructure linking discovery, development,
quality, and production into a single, coherent system.
By defining a unified digital thread spanning
materials, processes, equipment, and quality decisions, the proposed
architecture transforms bio fabrication from a collection of isolated
experimental workflows into a cyber-physical manufacturing platform. The
accompanying quantitative framework establishes, for the first time, a set of
cross-domain metrics reproducibility, scalability, execution discipline, and
documentation completeness that allow progress in bio fabrication to be
evaluated not only by construct performance, but by manufacturing readiness and
system maturity.
Although the numerical results
presented here are necessarily projected, their magnitude and direction are
consistent with decades of experience in regulated life sciences manufacturing.
This strongly suggests that the same architectural principles can enable organ
bioprinting to traverse the critical transition from laboratory demonstrations
to reliable, inspectable, multi-site production systems.
More broadly, the framework outlined in this work
provides a foundation for distributed, resilient bio fabrication manufacturing
networks, in which innovation, scale-up, and production can proceed in parallel
under a shared digital and quality governance model. Such an infrastructure is
not merely an enabler of scientific translation; it is a prerequisite for
transforming organ bioprinting into a dependable component of modern healthcare
systems.
In this sense, the central contribution of this
work is not specific software architecture, but a reframing of bio fabrication
itself: from an instrument-centered experimental practice into a manufacturing
discipline governed by systems engineering principles. It is this shift rather
than any single technological breakthrough that will ultimately determine
whether organ bioprinting achieves durable clinical and societal impact.
1. [1] Foundational Bioprinting Reviews (Context + Recent Advances) Mironov, V., et al. (2008) Title. Regenerative Medicine, 3, 93-103. The yellow ones are unknown. [2] Murphy, S.V. and Atala, A. (2014) 3D Bioprinting of Tissues and Organs. Nature Biotechnology, 32, 773-785. https://doi.org/10.1038/nbt.2958 [3] Groll, J., et al. (2016) Biofabrication: Reappraising the Definition of an Evolving Field. Bio Fabrication, 8, Article ID: 013001. [4] Mirsky, N.A., Ehlen, Q.T., Greenfield, J.A., Antonietti, M., Slavin, B.V., Nayak, V.V., et al. (2024) Three-Dimensional Bioprinting: A Comprehensive Review for Applications in Tissue Engineering and Regenerative Medicine. Bioengineering, 11, Article 777. https://doi.org/10.3390/bioengineering11080777 [5] Croxatto, A., et al. (2020) Title. Clinical Microbiology and Infection, 26, 712-718. [6] Yarbrough, M.L., Lainhart, W., McMullen, A.R., Anderson, N.W. and Burnham, C.D. (2018) Impact of Total Laboratory Automation on Workflow and Specimen Processing Time for Culture of Urine Specimens. European Journal of Clinical Microbiology & Infectious Diseases, 37, 2405-2411. https://doi.org/10.1007/s10096-018-3391-7 [7] Zhang, H., Wang, H., Shen, X., Jia, X., Yu, S., Qiu, X., et al. (2021) The Landscape of Regulatory Genes in Brain-Wide Neuronal Phenotypes of a Vertebrate Brain. eLife, 10, e68224. https://doi.org/10.7554/elife.68224 [8] Hartmann, J., Lauerwald, R. and Moosdorf, N. (2019) GLORICH—Global River Chemistry Database. PANGAEA. https://doi.org/10.1594/PANGAEA.902360 [9] Theparee, T., Das, S. and Thomson, R.B. (2018) Total Laboratory Automation and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Improve Turnaround Times in the Clinical Microbiology Laboratory: A Retrospec-tive Analysis. Journal of Clinical Microbiology, 56, e01242-17. https://doi.org/10.1128/jcm.01242-17 [10] Moon, S., Szlezák, N.A., Michaud, C.M., Jamison, D.T., Keusch, G.T., Clark, W.C., et al. (2010) The Global Health System: Lessons for a Stronger Institutional Framework. PLOS Medicine, 7, e1000193. https://doi.org/10.1371/journal.pmed.1000193 [11] Xu, H., Leinwand, S.G., Dell, A.L., Fried-Cassorla, E. and Raper, J.A. (2010) The Calmodulin-Stimulated Adenylate Cyclase ADCY8 Sets the Sensitivity of Zebrafish Retinal Axons to Midline Repellents and Is Required for Normal Midline Crossing. The Journal of Neuroscience, 30, 7423-7433. https://doi.org/10.1523/jneurosci.0699-10.2010 [12] Loukelis, K., Koutsomarkos, N., Mikos, A.G. and Chatzinikolaidou, M. (2024) Advances in 3D Bioprinting for Regenerative Medicine Applications. Regenerative Biomaterials, 11, rbae033. https://doi.org/10.1093/rb/rbae033 [13] Jose, J., Peter, A., Thajudeen, K.Y., Gomes Pereira, M.D.L., Bhat, S.G., et al. (2024) Recent Advances in the Design and Development of Bioink Formulations for Various Biomedical Applications. Results in Engineering, 22, Article ID: 102060. https://doi.org/10.1016/j.rineng.2024.102060 [14] Muñoz-Castiblanco, T., Moreno-Marín, J.P. and Osorio, M. (2025) Natural Mac-romolecule-Based Bioinks for 3D Bioprinting: A Systematic Review of Composi-tion, Physicochemical Characterization, and Biomedical Applications. Bioprinting, 48, e00407. https://doi.org/10.1016/j.bprint.2025.e00407 [15] Briones, Y., Pascua, B., Tiangco, N., Crisostomo, I., Casiguran, S. and Remenyi, R. (2025) Assessing the Landscape of Clinical and Observational Trials Involving Bi-oprinting: A Scoping Review. 3D Printing in Medicine, 11, Article No. 5. https://doi.org/10.1186/s41205-025-00253-2 [16] Standards and Industrial Practice (2024) ASTM Standard F3659-24, Standard Guide for Bi-Oinks Used in Bioprinting. ASTM International. Confirm yellow high-lighting information [17] ASTM F3659-24 (2024) Standard Guide for Bioinks Used in Bioprinting. Confirm yellow highlighting information [18] Briones, Y., Pascua, B., Tiangco, N., Crisostomo, I., Casiguran, S. and Remenyi, R. (2025) Assessing the Landscape of Clinical and Observational Trials Involving Bioprinting: A Scoping Review. 3D Printing in Medicine, 11, Article No. 5. https://doi.org/10.1186/s41205-025-00253-2 [19] Mirsky, N.A., Ehlen, Q.T., Greenfield, J.A., Antonietti, M., Slavin, B.V., Nayak, V.V., et al. (2024) Three-dimensional Bioprinting: A Comprehensive Review for Applications in Tissue Engineering and Regenerative Medicine. Bioengineering, 11, Article 777. https://doi.org/10.3390/bioengineering11080777 [20] Mihaylova, A., Shopova, D., Parahuleva, N., Yaneva, A. and Bakova, D. (2024) (3D) Bioprinting—Next Dimension of the Pharmaceutical Sector. Pharmaceuticals, 17, Article 797. https://doi.org/10.3390/ph17060797 [21] Quality Frameworks for Bio-Printing (2025) QMS and Regulatory Intersections: A Recent White-Paper Summary Outlining How Existing Regulatory and Quality Management Standards (e.g., ISO 13485, GMP, ATMP Frameworks) Map Onto Bi-Oprinting Practice, Reinforcing Quality Systems Discussions. The highlighted document may not actually be a document, or the author information may be incomplete. [22] Regulatory Perspective on 3D Bioprinting of Regenerative Medicine and Tissue Engineered Products (2024) Webinar-Series Perspective Addressing Contemporary Regulatory Views on Bioprinting Products and Associated Governance Considera-tions. [23] Legal and Regulatory Considerations for 3D Bioprinting (2025) A 2025 Review Ex-Plaining Legal and Regulatory Challenges, Reinforcing the Evolving Policy Landscape for Bioprinting Products. Bioprinting Technology and Informatics. [24] Schanze, et al. (2021) 3D Bioprinting: Current Status and Trends. publication in-formation/link. Is the author's name complete? [25] O’Connell, C.D., Dalton, P.D. and Hutmacher, D.W. (2024) Why Bioprinting in Regenerative Medicine Should Adopt a Rational Technology Readiness Assess-ment. Trends in Biotechnology, 42, 1218-1229. [26] Mirsky, N.A., et al. (2024) A Comprehensive Review of 3D Bioprinting Methods, Applications, and Translational Challenges in Tissue Engineering and Regenerative Medicine. publication information/link. [27] Briones, Y., Pascua, B., Tiangco, N., Crisostomo, I., Casiguran, S. and Remenyi, R. (2025) Assessing the Landscape of Clinical and Observational Trials Involving Bioprinting: A Scoping Review. 3D Printing in Medicine, 11, Article No. 5. https://doi.org/10.1186/s41205-025-00253-2 Confirm yellow highlighting infor-mation [28] Author (2022) 3D Bioprinting: Current Status and Trends. publication infor-mation/link. [29] Frontiers Review on Microspheres for 3D Bioprinting (2025) Relevant for Materials and Bioink Discussions, Including Fabrication and Application Paradigms. Infor-mation is confusing and the type cannot be determined. [30] Nature Biotechnology “Bioprinting” (2025) Peer-Reviewed perspective and syn-thesis on the state of bioprinting technologies and translational promise. [31] International Journal of Bioprinting (2025) Multiple peer-reviewed articles on 3D-printed microfluidic and organoid systems, useful for contextualizing manu-fac-turing and device integration. Standards Development Activities [32] ASME Bioprinter Standards Initiative - Discussion of ongoing standards work in-volving ASTM and IEEE for hardware interoperability and calibration in bioprinting equipment.
Niranjana Raghunathan conceived the study, developed the architectural framework and quantitative methodology, performed the literature analysis and systems synthesis, and wrote the manuscript.
This research received no external funding.
The authors declare no conflicts of interest regarding the publication of this pa-per.
Avoid the stilted expression, “One of us (R. B. G.) thanks...” Instead, try “R. B. G. thanks”. Do NOT put sponsor acknowledgements in the unnumbered footnote on the first page, but at here.
No clinical
trials or human subject studies were conducted as part of this work. The study
is based on publicly available literature and de-identified, aggregated
industrial reference data that cannot be shared due to confidentiality and
contractual restrictions. All conceptual frameworks, metric definitions, and
methodological descriptions necessary to reproduce the analytical approach are
provided within the article.